<DOC>
	<DOCNO>NCT01376479</DOCNO>
	<brief_summary>The purpose study evaluate safety immune response inactivate vaccine prevent hand , foot mouth disease ( HFMD ) cause Enterovirus 71 ( EV71 ) .</brief_summary>
	<brief_title>Safety Immunogenicity Study Inactivated Vaccine Against Hand , Foot Mouth Disease Caused Enterovirus 71</brief_title>
	<detailed_description>Hand , foot mouth disease ( HFMD ) cause Enterovirus 71 ( EV71 ) severely debilitate child risk paralysis death . The susceptible age group 1 5 year old , disease spread via oral-fecal route . Currently , antiviral therapy vaccine available prevent HFMD . In study , inactivate vaccine ( INV21 ) base EV71 antigen evaluate term safety immune response generate two dos vaccine give healthy adult . Safety assessment include frequency severity systemic adverse event well local reaction . Immune response assess measurement EV71 neutralize antibody level specify time point throughout study .</detailed_description>
	<mesh_term>Mouth Diseases</mesh_term>
	<mesh_term>Enterovirus Infections</mesh_term>
	<mesh_term>Foot-and-Mouth Disease</mesh_term>
	<mesh_term>Hand , Foot Mouth Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Male female age 21 45 year , inclusive , time screening In good health determine medical history physical examination . Normal clinical safety laboratory examination . Body mass index ( BMI ) range 1928 kg/m2 . Documented negative serology HIV , Hepatitis C antibody , Hepatitis B surface antigen . Females child bear potential must negative urine pregnancy test result screen negative urine pregnancy test immediately prior vaccination . Willing able give write informed consent participate . Willing able communicate Investigator understand requirement study . Low level EV71 neutralize antibody . Any medical , psychiatric , social condition , occupational reason responsibility , judgment investigator , contraindication protocol participation impair volunteer 's ability give inform consent Clinically significant hematological ( include bleed disorder ) , renal , hepatic , pulmonary ( include asthma ) , central nervous system ( include epilepsy , seizure , convulsion , chronic migraine ) , cardiovascular , gastrointestinal disorder , accord Investigator 's judgment . Ongoing rash dermatologic disease . Abnormal ECG assess Investigator . History diabetes mellitus . Hypersensitivity vaccine . History severe HFMD CNS involvement . Receipt vaccine 4 week precede first trial vaccination . Planned receipt vaccine 4 week follow vaccination study . History thymic pathology , thymectomy , myasthenia immunodeficiency . History recur migraine prescription medication treatment recur headache migraine . Positive urine test drug abuse . Females pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>HFMD</keyword>
	<keyword>EV71</keyword>
	<keyword>Enterovirus</keyword>
	<keyword>INV21</keyword>
	<keyword>Encephalitis</keyword>
</DOC>